UPC Analytics
ENDE
Analytics1Cases2Decisions4Judges5Parties2Firms
Filing trendsOutcomesPendencyTechnologyForum strategyLeading casesLegal issuesSecurity for costs

Outcome base rates

What's normal — PI grant rate, infringement rate, revocation rate, settlement rate. Honest denominators using motion type.

Legal principleA press release alone is insufficient evidence to demonstrate how accused software processes dataClear all
Patentee win rate
Share of merits decisions where the patentee prevailed — infringement cases finding infringement, revocation cases upholding the patent. Settled, withdrawn, and procedural-only outcomes excluded from the denominator.

No merits decisions in the current scope.

PI grant rate
0%
0 granted · 1 denied · 1 total decisions
PI grant rate (conservative)
0%
Granted / total PI decisions (incl. interim, withdrawn)
Infringement rate
—
Revocation rate
—
Settlement / withdrawal rate
Settled / withdrawn / dismissed as a share of all non-pending outcomes.
0% 0 / 1
By technology sector
Top sectors by case count (filter scope applied).
By case category
How outcome rates differ across the six L2 buckets.
  • Provisional measures1
By division
PI grant rate · infringement rate · revocation rate per division (within scope).
  • Paris LD1 casesPI grant rate: 0%Infringement rate: —Revocation rate: —
Recent decisions
Most recent decisions in scope.
  • 2026-01-23UPC_CFI_808/2025PI deniedThe Paris Local Division rejected Guardant Health's application for provisional measures under three patents (EP 3 591 073, EP 3 443 066, EP 3 766 986) against Sophia Genetics. The court found issues of added matter in the divisional patent and insufficient evidence to demonstrate infringement with the required degree of certainty. Guardant Health's request regarding a fourth patent (EP 3 470 533) was withdrawn during proceedings. Guardant Health ordered to pay Sophia Genetics EUR 400,000 as interim costs.
  • 2025-10-01UPC_CFI_808/2025Procedural onlyThe Paris Local Division issued a scheduling order for the oral hearing in Guardant Health's preliminary injunction application against Sophia Genetics entities based on four patents (EP 3 766 986, EP 3 470 533, EP 3 443 066, EP 3 591 073) relating to genomic analysis, after defendants failed to appoint representatives within 15 days of service.